LEH Pharma picks Syneos Health for better selling EyeMax lensOctober 22, 2018
LEH Pharma, a provider of revolutionary ocular implants for macular disorders, has picked Syneos Health, a fully integrated biopharmaceutical solutions organization, as its Global Clinical Development and Commercialisation Provider.
According to the press release, the aim of the relationship is faster commercialisation of LEH Pharma’s EyeMax lens, for the treatment of age-related macular degeneration (AMD). Through this relationship, LEH Pharma gains access to the industry’s only end-to-end biopharmaceutical solutions organization, including the industry’s largest Contract Commercial Organization (CCO) and a leading Contract Research Organization (CRO).
Syneos Health’s Integrated Solutions Group (ISG) will oversee the commercialisation of EyeMax, the company said in the press release. The ISG team will orchestrate Syneos Health’s vast clinical commercialisation capabilities and talent, sharing data and synthesized insights to drive efficiencies and speed. This will include providing strategic guidance to LEH Pharma by leveraging the company’s clinical, Real World Evidence, market access, clinical affairs, marketing communications and regulatory capabilities. Syneos Health will also provide LEH Pharma with Medical Science Liaisons (MSL), through a dedicated team that will provide training and support services to the Company’s affiliated surgeons for the use of the EyeMax lens.
Dr Bobby Qureshi, Founder and CEO of LEH Pharma, said: “We are delighted to enter into this relationship with Syneos Health. Their expertise and insight will be vital as we continue the commercial expansion of the EyeMax lens, which we believe has the potential to improve the quality of life of millions of AMD sufferers around the world whose needs are not adequately addressed.”
Alistair Macdonald, Chief Executive Officer of Syneos Health, said: “Syneos Health offers forward-thinking biopharmaceutical companies a unique outsourcing model for comprehensive commercialisation, designed to improve the likelihood of launch and market success. We are pleased to provide this approach to LEH Pharma, maximizing returns throughout the product lifecycle and expanding the availability of their much needed product to patients worldwide.”